Equality Impact Assessment (EQIA)
Total Page:16
File Type:pdf, Size:1020Kb
EQUALITY IMPACT ASSESSMENT When completed, a copy of this EQIA form should be emailed to [email protected] Name of Strategy West of Scotland Cancer Network Systemic Anti-Cancer Therapy Future Service Delivery Plan Name of Division Acute Services Names and role of First face to face meeting Date(s) of 16 April 2019 and ongoing Review Team: Nicky Batty, MacMillan Practice Development Facilitator assessment: virtual engagement. The EQIA is updated on an Acute Cancer ongoing basis and shared Sharon Bleakley, Scottish Health Council fortnightly with the full Gillian Carle, Staff Nurse Chemotherapy Programme Amanda Lindsay, Patient Representative Board for comments/updates. Peter MacLean, Clinical Director – Cancer Services / A list of programme board Consultant Haematologist members is included at Sandra McCall, Ayrshire Cancer Support Appendix 1. Caroline Rennie, Macmillan Nurse Consultant Elaine Savory, Equality and Diversity Adviser Emma Smith, Senior Charge Nurse Second face to face meeting 8 August 2019 Patient Representatives: Shoana Connell, Josephine Cosgrove, Ian Dalgleish, Carol-Anne Garven, John Jackson, Shona Kinniburgh, James McBroom, Sinclair Molloy, Anne Riddell, Shirley Risden, Annie Small, William Steele, Alan Tattersfield Nicky Batty, MacMillan Practice Development Facilitator Acute Cancer Sandra McCall, Ayrshire Cancer Support Caroline Rennie, Macmillan Nurse Consultant Elaine Savory, Equality and Diversity Adviser 1 Wendy Short, Senior Charge Nurse PART ONE: RAPID IMPACT ASSESSMENT (INITIAL SCREENING PROCESS) SECTION ONE AIMS OF THE PROGRAMME 1.1. Is this a new or existing Policy : New regional policy for local implementation 1.2. What is the aim or purpose of the Strategy: Definition of Terms SACT (Systemic Anti-Cancer Therapy) - this includes traditional Cytotoxic chemotherapy as well as the full range of newer biological and immunological therapies used as treatment for cancer. For the purposes of this paper it is simpler to refer to these all together as Chemotherapy. NHS AA (NHS Ayrshire & Arran) NHS GGC (NHS Greater Glasgow and Clyde) BWoSCC (Beatson West of Scotland Cancer Centre) WoSCAN (West of Scotland Cancer Network) – this is one of three cancer networks in Scotland comprising 4 Health Boards (NHSAA, NHSGGC, NHS Lanarkshire and NHS Forth Valley). To maintain and develop a safe service for the delivery of chemotherapy within NHS Ayrshire & Arran in conjunction with Boards within WoSCAN. There are significant pressures in relation to chemotherapy delivery due to a gradual increase in new presentations of cancer but more due to a rapid increase in the treatment options available. This means that chemotherapy is available for some patients where it would not have been in the past, and that for many patients additional chemotherapy options are available beyond those previously available. The current model of care: Cancer Centre • Treatment for all Cancers • Routine and complex SACT • Chemoradiotherapy • Broad trial portfolio (phase 1,2 and 3) • Physical capacity significantly challenged by demand Cancer Units • Treatment for 5 main tumour types • Variable trial access (phase 3) 2 • Dispersed workforce • Imbalanced staffing and physical capacity The emerging service model: Cancer Centre (Tier 1) • Complex treatments • Treatment for rare cancers Population 2.7 million • Chemoradiotherapy One for WoS • Phase 1 and 2 clinical trials Cancer Units (Tier 2) • Multidisciplinary teams (consultant and NMP) • Treatment for main tumour types and some less common Population 300,000 to cancers 600,000 • Long infusions (more than 4 hours) 4 or 5 for WoS • Phase 3 clinical trials Outreach (Tier 3) • Nurse led service • Simple short infusions Population 150,000 to • Subcutaneous treatments 300,000 • Supportive medicines (for example, bisphosphonates) 10 to 15 for WoS Community • Dispensing of selected oral SACT • Primary care shared care • Delivery of supportive medicines • Community staff delivery 3 The increased volume and complexity of available chemotherapy, as shown in the following table, puts pressure on the clinical teams assessing patients and prescribing treatment, and on the clinical pharmacy teams providing the validation safety checks. Summary Table of Activity by Year Year Regimen added Current 3 yr total 3 year overall as % of all Tumour Group 2017 2018 2019 Total total regs Haem-onc 18 21 32 71 208 34.1% Breast 6 7 16 29 75 38.7% Lung 3 9 15 27 59 45.8% Colorectal 5 0 0 5 41 12.2% Urological 2 0 2 4 26 15.4% Grand Total 34 37 65 136 409 33.3% NOTE: all totals exclude trials There are also physical accommodation and workforce pressures in aseptic pharmacy and on the daycase units where the chemotherapy is delivered by specialist nursing teams. These pressures are not unique to NHS A&A and we have been active participants in the work which has led to a regional approach to service improvement. The WoSCAN SACT future service delivery plan has been endorsed by the Boards with the network including NHS A&A. Our local strategy is therefore to implement this plan within Ayrshire to support safe and effective care delivery for patients and staff. The plan is based upon a tiered model of care with one Tier 1 centre for the whole of WoS region , currently Beatson WoSCC, with one Tier 2 site for Ayrshire and as many Tier 3 sites as needed. The Tier 1 site will offer specialist care for less common cancers, for the purposes of this review this will include the clinical assessment and chemotherapy prescribing for these cancers. The one Tier 2 site for Ayrshire will be situated within one of the two existing University Hospital sites and will provide a base for prescribing and clinical pharmacy validation for the majority of chemotherapy given locally. Tier 2 will also be the site for high risk daycase, and all inpatient chemotherapy delivery. Tier 3 will offer a safe, local environment for low risk daycase chemotherapy delivery. Tier 3 will be delivered by chemotherapy trained nursing staff but will generally not be supported by medical or clinical pharmacy teams. The best sites for Tier 3 will be determined by patient demographic and availability of appropriate accommodation. This means that patients will travel to the cancer unit for assessment, unless telephone or online assessment is appropriate, and that the majority of patients will get treatment either at their local hospital or outreach centre. 4 Less common cancers will be assessed and prescribed at the Tier 1 site but treatment may be delivered within a Tier 2 or 3 site depending on the level of risk. Implementation of a model of central assessment at the cancer centre with delivery of treatment at local cancer unit or outreach centres, for some patients groups, would allow for care of patients to remain under the appropriate specialist team whilst receiving treatment closer to home thus reducing travel for patients and carers. For example, patients with melanoma are currently treated at BWoSCC however, the majority of treatments delivered for this patient group are suitable for local delivery, as these treatments are already being provided at local units for other patient groups. By repatriating relevant service users the service hopes to: • Move care closer to home, where feasible and safe to do so, to improve the patient experience whilst maintaining high quality outcomes • Optimise the use of the existing BWoSCC • Release capacity in the BWoSCC to focus on more complex treatments and clinical trials Telephone assessment and online electronic assessment (My Clinical Outcomes) are currently being used where appropriate to minimise travel for assessment. It is anticipated that the use of these methods will expand and Attend Anywhere, which is a web-based platform that allows health care providers to offer video call access to their services, may be implemented. However, we are mindful that across Ayrshire wifi connection is variable and therefore, this service may not be available for all. The Scottish Government’s digital ambition for Scotland is for Next Generation Broadband to be available to all by 2020. The graphics below show the ongoing work to improve this across the 3 localities. East Ayrshire North Ayrshire South Ayrshire 5 1.3. Who is this strategy intended to benefit or affect? In what way? Who are the stakeholders? Patients and Carers Staff (Medical, Nursing, Pharmacy) Laboratory Services Supporting clinical services (Radiology, Cardiology, Renal, etc) GPs Scottish Ambulance Service External providers e.g. Beatson based Specialist Oncology Service Voluntary/ Charity Sector including MacMillan, Ayrshire Cancer Support, Troon and Irvine Cancer Care, North Ayrshire Cancer Care, CAN Scottish Health Council – the SCH representative is involved via the Programme Board and the Working Group Local Authority partners The process will ensure all groups are informed using verbal and written communication. All groups will be able to engage in the process either via the questionnaire or face to face meetings. The key stakeholders are all included in the Chemotherapy Programme Board and will receive regular communication regarding the review process. 1.4. What is the socio-economic impact of this policy / service change? (The Fairer Scotland Duty places responsibility on Health Boards to actively consider how they can reduce inequalities of outcomes cause by socio-economic disadvantage when making strategic decisions) 6 The Scottish Index of Multiple Deprivation (SIMD) identifies small area concentrations of multiple deprivation across Scotland. It is made up of seven domains constructed from 38 indicators that are used to measure multiple aspects of deprivation. The domains and their weighting are income; employment; health; education, skills and training; geographic access to services; crime and housing. The SIMD ranges from SIMD1 being the most deprived to SIMD 5 being the least deprived area. SIMD identifies deprived areas, not deprived individuals. It is the most accessible and consistent measure available for targeting resources to those communities experiencing the most multiple deprivation. Many programmes of work within NHS Ayrshire and Arran utilise SIMD with the overarching aim of reducing inequalities in health.